XTL Biopharmaceuticals (XTLB) Competitors

$2.56 +0.07 (+2.89%)

As of 01:48 PM Eastern

XTLB vs. TXMD, VYNE, LPCN, NCEL, and TRAW

Should you buy XTL Biopharmaceuticals stock or one of its competitors? MarketBeat compares XTL Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XTL Biopharmaceuticals include TherapeuticsMD (TXMD), VYNE Therapeutics (VYNE), Lipocine (LPCN), NLS Pharmaceutics (NCEL), and Traws Pharma (TRAW). These companies are all part of the "med - drugs" industry.

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

TherapeuticsMD has a net margin of 5.34% compared to XTL Biopharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat XTL Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
XTL Biopharmaceuticals	N/A	N/A	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.24	-$570K	$0.06	35.83
XTL Biopharmaceuticals	$450K	12.53	-$1.03M	-$0.64	N/A

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
XTL Biopharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Summary

TherapeuticsMD beats XTL Biopharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

XTL Biopharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. XTL Biopharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

In the previous week, VYNE Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for XTL Biopharmaceuticals. VYNE Therapeutics' average media sentiment score of 1.50 beat XTL Biopharmaceuticals' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

XTL Biopharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

XTL Biopharmaceuticals has higher earnings, but lower revenue than VYNE Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	12.53	-$1.03M	-$0.64	N/A
VYNE Therapeutics	$570K	39.32	-$26.48M	-$0.38	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

VYNE Therapeutics beats XTL Biopharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

XTL Biopharmaceuticals has lower revenue, but higher earnings than Lipocine. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$2.00M	9.22	-$9.63M	-$1.88	N/A
XTL Biopharmaceuticals	$450K	12.53	-$1.03M	-$0.64	N/A

Lipocine has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Lipocine presently has a consensus price target of $15.00, suggesting a potential upside of 569.94%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts plainly believe Lipocine is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Lipocine shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Lipocine and 1 mentions for XTL Biopharmaceuticals. Lipocine's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XTL Biopharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XTL Biopharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
XTL Biopharmaceuticals	N/A	N/A	N/A

Summary

XTL Biopharmaceuticals beats Lipocine on 8 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
XTL Biopharmaceuticals	Neutral

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
XTL Biopharmaceuticals	$450K	12.53	-$1.03M	-$0.64	N/A

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
XTL Biopharmaceuticals	N/A	N/A	N/A

NLS Pharmaceutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals beats NLS Pharmaceutics on 6 of the 6 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Traws Pharma presently has a consensus price target of $8.00, suggesting a potential upside of 436.91%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Traws Pharma is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Traws Pharma had 10 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 11 mentions for Traws Pharma and 1 mentions for XTL Biopharmaceuticals. Traws Pharma's average media sentiment score of 0.70 beat XTL Biopharmaceuticals' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Traws Pharma has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	5.43	$9.17M	-$1.69	N/A
XTL Biopharmaceuticals	$450K	12.53	-$1.03M	-$0.64	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
XTL Biopharmaceuticals	N/A	N/A	N/A

Traws Pharma has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Summary

Traws Pharma beats XTL Biopharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.75M	$3.02B	$6.38B	$12.34B
Dividend Yield	N/A	1.96%	2.79%	5.33%
P/E Ratio	-4.09	17.77	20.91	25.65
Price / Sales	12.53	301.47	543.80	85.61
Price / Cash	N/A	57.57	44.13	56.16
Price / Book	1.04	4.59	10.09	7.06
Net Income	-$1.03M	$74.99M	$3.55B	$335.04M
7 Day Performance	-1.84%	0.14%	4.71%	2.60%
1 Month Performance	-4.40%	-4.86%	1.43%	1.42%
1 Year Performance	N/A	35.48%	36.72%	35.67%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.1174 of 5 stars	$2.56 +2.9%	N/A	N/A	$5.75M	$450K	N/A	N/A
TXMD TherapeuticsMD	0.5642 of 5 stars	$2.02 +3.6%	N/A	+44.5%	$22.57M	$3.02M	N/A	420	Positive News
VYNE VYNE Therapeutics	1.1916 of 5 stars	$0.67 +1.5%	N/A	-32.2%	$21.99M	$570K	N/A	30	Positive News Earnings Report Gap Down
LPCN Lipocine	2.8703 of 5 stars	$2.32 -0.4%	$15.00 +546.6%	-38.7%	$19.21M	$1.98M	N/A	10
NCEL NLS Pharmaceutics	0.7005 of 5 stars	$3.24 -2.7%	N/A	-81.5%	$17.80M	N/A	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. TXMD, VYNE, LPCN, NCEL, and TRAW

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Summary

How does XTL Biopharmaceuticals compare to Traws Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. TXMD, VYNE, LPCN, NCEL, and TRAW

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Is TXMD or XTLB more profitable?

Do insiders and institutionals have more ownership in TXMD or XTLB?

Which has better earnings and valuation, TXMD or XTLB?

Does the media favor TXMD or XTLB?

Do analysts recommend TXMD or XTLB?

Which has more volatility and risk, TXMD or XTLB?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Do analysts rate XTLB or VYNE?

Is XTLB or VYNE more profitable?

Does the media prefer XTLB or VYNE?

Which has more risk and volatility, XTLB or VYNE?

Which has better earnings and valuation, XTLB or VYNE?

Do institutionals & insiders believe in XTLB or VYNE?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Which has preferable valuation and earnings, LPCN or XTLB?

Which has more risk & volatility, LPCN or XTLB?

Do analysts prefer LPCN or XTLB?

Do insiders & institutionals believe in LPCN or XTLB?

Does the media favor LPCN or XTLB?

Is LPCN or XTLB more profitable?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Do analysts prefer NCEL or XTLB?

Does the media favor NCEL or XTLB?

Which has stronger earnings and valuation, NCEL or XTLB?

Is NCEL or XTLB more profitable?

Which has more volatility & risk, NCEL or XTLB?

Do insiders & institutionals hold more shares of NCEL or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Traws Pharma?

Do analysts rate TRAW or XTLB?

Does the media favor TRAW or XTLB?

Do institutionals & insiders hold more shares of TRAW or XTLB?

Which has better earnings and valuation, TRAW or XTLB?

Is TRAW or XTLB more profitable?

Which has more risk and volatility, TRAW or XTLB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools